Insilicofirst - New Collaboration in Toxicity Assessment

April 3, 2009 - Leadscope, Lhasa Limited, Multicase and Molecular Networks GmbH have launched a new collaboration providing toxicity assessment through a single common user interface. The new collaboration is Insilicofirst.

Insilicofirst brings together the world's leading organizations in toxicity prediction systems. This partnership combines highly regarded scientific knowledge with expertise in toxicity assessment through in silico predictive software development.

The initial phase of this collaboration, now available, is the development of a common user interface using the four founding partners' respective toxicity tools. Through insilicofirst.com scientists can obtain toxicity information, from all four partners, through a single query.

A query can be entered via a Mol/SD file, SMILES, Compound/Synonym Name or Registry Number. Data available includes model predictions, metabolism and reactivity) and published data. Users' initial search to see what data are available through Insilicofirst can be performed at no cost. The system completes a similarity search for analogs and also determines which models are appropriate for the query compound based on a domain of applicability analysis. Based on these analyses, the available products are shown along with their associated cost. Users can limit their search criteria by categories (i.e. carcinogenicity, genotoxicity, chronic, skin sensitization, etc), by product types (model predictions, metabolism and reactivity or published data) or by Vendors.

The Insilicofirst collaboration addresses the need to reduce the amount of time spent by scientists in referencing disparate sources of data to aid decision making related to toxicity assessment. Also, it will offer an efficient and cost-effective response to the EU REACH legislation and the desire to reduce animal testing.

To find out more about the Insilicofirst collaboration please visit insilicofirst.com.

Loftus Lucas
CEO, Leadscope, Inc.

David Watson
CEO, Lhasa Limited

Giles Klopman
CEO, Multicase

Johann Gasteiger
CEO, Molecular Networks, GmbH

Leadscope to Collaborate with Prof. Klaus Kümmerer to provide Environmental Databases and Predictive Models

Columbus, Ohio March 25, 2009 - Leadscope is pleased to announce a collaboration with Prof. Klaus Kümmerer and his group at the University Medical Center Freiburg in Germany to develop high quality environmental databases and predictive models.

An initial series of high quality curated databases will be based on the OECD 301C test. Additional databases and models will become available in the coming months. These databases will be available through the Leadscope and the Insilicofirst web sites.

"We are pleased to be licensing the high quality environmental databases and predictive models from Prof. Klaus Kümmerer's group," explains Mr. Loftus Lucas, Leadscope's CEO. "These databases and models will immediately support product development needs and regulatory submission requirements."

Prof. Klaus Kümmerer explains, "The biodegradability databases and models to be made available will contain information curated from public sources and data generated in our laboratories."

About Leadscope, Inc.

Leadscope's mission is to accelerate the drug discovery process by providing decision support based on regulatory and high quality data from research and development groups. The Company provides solutions which allow researchers to combine their own proprietary data with newly released U.S. FDA Toxicity Databases (based on the ToxML format).

The expertise of Leadscope includes an in-depth knowledge of advanced informatics and prediction technology along with the database services necessary to help organizations effectively analyze and visualize the valuable knowledge contained in research data.

Leadscope's customers include many pharmaceutical, chemical and consumer products companies, in addition to regulatory agencies in Europe, Japan, Canada and the United States.

About Prof. Klaus Kümmerer

Prof. Dr. Klaus Kümmerer, the founder of EDC, studied chemistry in Wurzburg and Tübingen and completed an additional training in ecology. He received his doctorate in 1990 from the Eberhard Karls University in Tübingen. Subsequently he became a manager in a private commercial research institution. He was awarded the title of professor in 1999 in the areas of environmental chemistry and environmental hygiene at the Albert Ludwig University in Freiburg. He has been a professor at the Department of Environmental Health Sciences at the University Medical Centre Freiburg since 2005. He is also the founder of EDC - Evaluation and Design of Chemicals.

Insilico Software Specialists Launch a Pioneering Development in Toxicity Assessment at the 48th Annual SOT

(PRWEB) March 13, 2009 -- Lhasa Limited, together with partners Multicase, Leadscope and Molecular Networks GmbH, will unveil the Insilicofirst project at the 48th Annual Meeting of the Society of Toxicology. The Insilicofirst launch event will take place on Monday 16th March at 6pm at the Sheraton Inner Harbor. Invited delegates will be able to meet representatives from all four collaborating organisations, and find out more about the Insilicofirst system. There is no charge to participate in the session, nor is there a need to be registered for the SOT Annual Meeting.

The event will include a project overview and demonstration of the new Insilicofirst common user interface. In addition there will be an opportunity for networking, with refreshments provided.

There are only a limited number of places remaining, if you would like to be considered as a delegate, please email marketing@lhasalimited.org expressing why this project is of interest to you.

Insilicofirst brings together the world's leading organisations in toxicity prediction systems. This is a partnership combining highly regarded scientific knowledge with expertise in in silico predictive software development. This strategic alliance has a ground breaking plan to develop an integrated prediction system to support environmental toxicological assessment.

The four partners are currently completing the first step towards achieving their challenging objective, as development of a common user interface using their respective toxicity tools nears completion. The Insilicofirst alliance will soon begin work on an integrated prediction system to support environment toxicological assessment, an area not covered by their existing tools.

Via one simple interface the new environmental toxicity application will integrate tools commonly available for in silico prediction to provide data and predictions relating to the environmental impact of a chemical structure input by the user. Such a novel development has clear and appealing attraction to many players within the field of environmental toxicology.

The Insilicofirst collaboration will address the need to reduce the amount of time spent by scientists in referencing disparate sources of data to aid decision making related to environmental toxicity.

Also, it will offer an efficient and cost-effective response to the EU REACH legislation and the desire to reduce animal testing. Financial and time costs will be dramatically reduced through the provision of a predictive in silico device containing a high quality knowledge base built from diverse and reliable data sources.

At the 48th SOT meeting in March 2009, the Insilicofirst alliance will demonstrate for the first time the collaborative path they will pursue in creating the world's fastest and most user-friendly suite of tools to support the prediction of environmental toxicity.

If you would like to register your interest in this event please email marketing@lhasalimited.org. To find out more about the Insilicofirst project please visit www.Insilicofirst.com.

Leadscope Announces the Appointment of Dr. Glenn Myatt as Chief Scientific Officer

Columbus, Ohio November 1, 2008 Leadscope announces the appointment of Dr. Glenn Myatt as Chief Scientific Officer. Dr. Myatt has held a number of scientific positions and was one of the founders of Leadscope in 1997.

"Dr. Myatt will be responsible for working with our customers and partners to ensure current and future products make a difference," says Loftus Lucas, CEO of Leadscope.

"With the recent completion of the FDA QSAR models, the FDA databases, the predictive data miner, and ToxML database builder, Leadscope is ideally position to provide a complete in silico discovery solution, " says Dr. Myatt. "I am excited to be taking on this new role."

About Leadscope
Leadscope's mission is to accelerate the drug discovery process by providing decision support based on regulatory and high quality data from research and development groups. The Company provides solutions which allow researchers to combine their own proprietary data with newly released U.S. FDA Toxicity Databases (based on the ToxML format).

The expertise of Leadscope includes an in-depth knowledge of advanced informatics and prediction technology along with the database services necessary to help organizations effectively analyze and visualize the valuable knowledge contained in research data.

Leadscope's customers include many pharmaceutical, chemical and consumer products companies, in addition to regulatory agencies in Europe, Japan, Canada and the United States.

Leadscope Announces the Availability of the FDA QSAR Toxicity Models

Columbus, Ohio August 17, 2008 - Leadscope announces the availability of the Leadscope FDA QSAR Toxicity Models.

Leadscope is making the FDA QSAR Toxicity Models available through a Cooperative Research & Development Agreement with the U.S. Food & Drug Administration (FDA). These models allow scientists to predict the potential toxicity and adverse human clinical effects of pharmaceuticals, cosmetics, food ingredients and other chemicals.

The Models are constructed by FDA scientists based on both proprietary and non-proprietary data. Leadscope technology allows delivery of models without disclosing any training sets.

The FDA QSAR Toxicity Models will be distributed via annual licenses in Suites containing multiple models relative to specific biological endpoints. The following Suites are now available:

A scientist may enter a single compound or a batch of compounds and receive predictions across multiple endpoints. The FDA QSAR Toxicity Models are a stand-alone product not requiring any other software or training.

Loftus Lucas, Leadscope's CEO, said, "The release of these FDA QSAR Toxicity Models culminates several years of work with the FDA to bring their toxicity data to scientists in an easy to use system. Scientists will get the same prediction from these Models as an FDA Regulator".

To view the FDA QSAR Model Suites visit Leadscope's website at www.leadscope.com/fda_qsar_models. For further information or to request on-line demonstration with a Leadscope scientist, contact us at info@leadscope.com.

Leadscope Announces the Availability of the FDA SAR-Ready Carcinogenicity Database

Columbus, Ohio August 1, 2008 - Leadscope announces the availability of the FDA SAR-Ready Carcinogenicity Database.

The FDA SAR-Ready Carcinogenicity database has been constructed by Leadscope and the U.S. Food & Drug Administration (FDA) under their Cooperative Research & Development Agreement. This database contains 1,634 SAR structures with 9,557 test results, compiled from non-proprietary FDA records and other sources. Structures are provided in the SAR, neutral and tested forms.

All structures and test calls have been verified for accuracy while both structures and data have been balanced to facilitate model training set selection. Toxicity endpoints include Rat Male, Rat Female, Mouse Male and Mouse Female.

Loftus Lucas, Leadscope's CEO, said, "The combination of SAR-ready data and Leadscope's model building capability allows scientists to easily build and apply transparent carcinogenicity models".

To view a pre-recorded demonstration of the FDA SAR-Ready Carcinogenicity database, Click Here. For further information on this new database or to request on-line demonstration with a Leadscope scientist contact us at info@leadscope.com.

About Leadscope, Inc.

Leadscope's mission is to accelerate the drug discovery process by providing decision support based on regulatory and high quality data from research and development groups. The Company provides solutions which allow researchers to combine their own proprietary data with newly released U.S. FDA Toxicity Databases (based on the ToxML format).

The expertise of Leadscope includes an in-depth knowledge of advanced informatics and prediction technology along with the database services necessary to help organizations effectively analyze and visualize the valuable knowledge contained in research data.

Leadscope's customers include many pharmaceutical, chemical and consumer products companies, in addition to regulatory agencies in Europe, Japan, Canada and the United States.

Contact:
Loftus Lucas
Leadscope, Inc.
1393 Dublin Road
Columbus, Ohio 43215
Phone: 614-340-1399
Fax: 614-675-3732
Email: info@leadscope.com